RB1 and esophageal cancer: For example, whether the nuclear expression of RB protein in IHC sections, as was used in the clinical trial of palbociclib in gastric and esophageal cancers, adequately predicts activity of the inhibitor or correlates with genomic deletions is unknown [18].